Recent Developments at Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is currently under investigation due to allegations of potential securities fraud. This inquiry is being conducted by Pomerantz LLP, a well-respected law firm known for its expertise in corporate and securities class action litigation.
Details of the Investigation
Investors who are worried about their holdings in Actinium are encouraged to contact the legal team at Pomerantz. Danielle Peyton serves as the main point of contact for anyone seeking more information about possible claims. The investigation is primarily examining whether Actinium, along with some of its executives and directors, may have participated in unethical business practices or fraud.
Regulatory Update and Impact on Stock
In a significant development, Actinium recently issued an important press release regarding its Biologics License Application (BLA) for Iomab-B, a treatment designed for patients with active relapsed or refractory acute myeloid leukemia. The announcement revealed that the U.S. Food and Drug Administration found the Phase 3 SIERRA trial insufficient to support the BLA filing. As a result, Actinium's stock price took a dramatic hit, plummeting by $3.69, which translates to a decline of about 59.81%, bringing the share price down to $2.48.
Pomerantz LLP: A Legacy in Class Action Law
Founded over 85 years ago by Abraham L. Pomerantz, Pomerantz LLP has established itself as a leader in corporate law and investor protection. The firm has consistently focused on addressing corporate misconduct, securities fraud, and breaches of fiduciary duty throughout its history. With offices in major cities such as New York, London, and Tel Aviv, Pomerantz remains a strong advocate for the rights of investors.
Contact Information for Concerned Investors
Those who wish to pursue justice or learn more about the status of their claims can reach out to Danielle Peyton at Pomerantz LLP via email or phone to discuss their options.
Frequently Asked Questions
What is the investigation concerning Actinium Pharmaceuticals?
The investigation is focused on whether Actinium Pharmaceuticals and certain executives may have engaged in securities fraud or other illegal business practices.
How did Actinium's stock price react to the recent announcement?
The stock price saw a significant decrease of 59.81%, dropping $3.69 per share following the FDA's announcement.
Who should I contact if I have concerns about my investment?
Investors can contact Danielle Peyton at Pomerantz LLP for help with their concerns regarding their investments in Actinium Pharmaceuticals.
What is the significance of the Biologics License Application for Iomab-B?
The BLA filing is essential for obtaining commercial approval for Iomab-B, a treatment for acute myeloid leukemia, which could have a major impact on patient care and the company's future prospects.
What has been Pomerantz LLP's track record?
Pomerantz LLP has a distinguished history of recovering billions in damages for class members through its extensive work in securities and corporate class actions.
